Sign In to View Organizational & Contract Pricing.
Select a Size
To inquire about this product F7307, please contact your local Merck office or dealer. Contact Technical Service
About This Item
Empirical Formula (Hill Notation):
C9H19ClN3O5P
CAS Number:
Molecular Weight:
315.69
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
protect from light
Skip To
InChI
1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)
SMILES string
CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O
InChI key
YAKWPXVTIGTRJH-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
protect from light
color
light yellow
solubility
H2O: ≥1 mg/mL
originator
Servier
storage temp.
2-8°C
Biochem/physiol Actions
Fotemustine is a third generation nitrosourea, chloroethylating agent used in the treatment of glioma and malignant melanoma.
Features and Benefits
This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Servier. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
A Farolfi et al.
Journal of chemotherapy (Florence, Italy), 23(5), 300-305 (2011-10-19)
The liver is the primary site of metastases in most uveal melanoma patients. We retrospectively investigated intraarterial chemotherapy (IAC) as treatment for patients with hepatic melanoma metastases.Twenty-three patients (18 with uveal melanoma) received fotemustine (14 patients, 61.9%) or carboplatin (9
Aleksandra Ristić-Fira et al.
Radiation protection dosimetry, 143(2-4), 503-507 (2010-12-25)
Response of human HTB140 melanoma cells to proton irradiation in combination with fotemustine (FM) was investigated. Effects of these agents were analysed on cell proliferation and induction of apoptosis. Cells pretreated with 100- or 250-µM of FM were irradiated in
Thierry Passeron et al.
Experimental dermatology, 20(12), 1030-1032 (2011-11-19)
Selection for targeted therapies in melanoma is currently based on the search for mutations in selected genes. We aimed at evaluating the interest of signalling and chemosensitivity studies in addition to genotyping for assessing the best suitable treatment in an
Alessandro Paccapelo et al.
Journal of translational medicine, 10, 90-90 (2012-05-16)
At recurrence the use of nitrosoureas is widely-used as a therapeutic option for glioblastoma (GBM) patients. The efficacy of fotemustine (FTM) has been demonstrated in phase II clinical trials; however, these papers report a wide range of progression-free-survival (PFS-6 m)
Felice Vito Vitale et al.
Anticancer research, 31(12), 4553-4559 (2011-12-27)
Locoregional treatments represent a good option for patients suffering from hepatocellular carcinoma (HCC) not eligible for resection or transplantation. Locoregional approaches include a wide spectrum of therapeutic methods and hepatic intra-arterial drug infusion is also considered. Fotemustine is a chemotherapy
Articles
Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.
Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service